Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Debt Repayment
Cash used to repay borrowings during the period.
Exagen Inc.NASDAQ: XGN
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment grows, but more slowly than its trailing trend
Q1 FY2026 debt repayment of $357K (cash outflow) rose 36.3% year over year, behind the +308.6% change in trailing-twelve-month debt repayment. Sequentially, it rose 3.2% from the prior quarter.
Context
- Debt repayment amounted to 3.0% of revenue in FY2025, up 1.5 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +36.3% toward the trailing-twelve-month pace of +308.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 2.01M USD
- Year-over-year change
- +333.7%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.01M | +333.7% |
| FY2024 | 2024-12-31 | (861K) | +92.1% |
| FY2023 | 2023-12-31 | (10.94M) | -1471.6% |
| FY2022 | 2022-12-31 | (696K) | -32.6% |
| FY2021 | 2021-12-31 | (525K) | — |
Debt Repayment vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 debt repayment of $1.92M is the 8th largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +308.6% is the 2nd highest of 8, against a peer median of +86.4%.
- Debt repayment amounts to 2.8% of revenue for XGN, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $21.6M | +86.4% | -0.8% | 20.0% | |
| LTM Jun 2026 | $16M | +108.0% | +542.7% | 2.1% | |
| LTM Mar 2026 | $12.07M | -144.2% | — | 11.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $6M | +0.0% | — | 58.2% |
| LTM Mar 2026 | $5.13M | — | -30.6% | 3.8% | |
| LTM Mar 2026 | $2.36M | +318.1% | — | 1.1% | |
| LTM Mar 2026 | $2.15M | +93.3% | -52.2% | 5.1% | |
| LTM Mar 2026 | $1.92M | +308.6% | — | 2.8% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding XGN) | $0 | +86.4% | -15.7% | 2.9% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| Deferred Income Tax | 148K | (306K) | 0 | 0 | 0 |
| Stock-Based Compensation | 4.73M | 4.7M | 3.62M | 1.76M | 2.16M |
| Change in Working Capital | (61K) | 1.67M | 325K | (3.08M) | (1.98M) |
| Accounts Receivables | (744K) | 3.58M | (474K) | (1.28M) | (3.02M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (655K) | 901K | 67K | 308K | 42K |
| Other Working Capital | 1.34M | (2.81M) | 732K | (2.1M) | 997K |
| Other Non-Cash Items | 819K | 7.62M | 3.12M | 1.43M | 4.03M |
| Operating Cash Flow | (20.27M) | (32.14M) | (14.46M) | (13.28M) | (13.63M) |
| Capital Expenditures | (2.37M) | (4.32M) | (828K) | (515K) | (641K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 15K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (50K) | 0 | 24K | 0 | 0 |
| Investing Cash Flow | (2.42M) | (4.32M) | (804K) | (515K) | (626K) |
| Debt Repayment | (525K) | (696K) | (10.94M) | (861K) | 2.01M |
| Common Stock Issued | 69.14M | 446K | 306K | 198K | 22.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.94M) | (239K) | 0 | 0 | 0 |
| Financing Cash Flow | 64.68M | (489K) | (10.63M) | (663K) | 24.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.99M | (36.95M) | (25.9M) | (14.46M) | 10.18M |
| Free Cash Flow | (22.64M) | (36.46M) | (15.29M) | (13.79M) | (14.27M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.